Adenoma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Adenoma]] | |||
Adrenal adenoma must be differentiated from other adrenal tumors such as , adrenal [[metastasis]], [[Pheochromocytoma|adrenal medullary tumors]], and [[Cushing's syndrome]]. | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center" | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}} | |||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}} | |||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Imagings}} | |||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Laboratory tests}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Adrenocortica'''l carcinoma | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Mass effect symptoms | |||
* Symptoms related to excess [[glucocorticoid]] | |||
* Symptoms related to excess [[mineralocorticoid]] | |||
* Symptoms related to excess [[androgen]] or [[estrogen]] secretion | |||
| | |||
* Irregular shape | |||
* Non-[[homogeneous]] density because of central areas of low attenuation due to [[tumor]] [[necrosis]] | |||
* [[Tumor]] [[calcification]] | |||
* Diameter usually >4 cm | |||
* Unilateral location | |||
* High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU) | |||
* Non-[[homogeneous]] enhancement on [[Computed tomography|CT]] with [[intravenous]] [[Contrast medium|contrast]] | |||
* Delay in [[contrast medium]] washout (10 minutes after administration of [[contrast]], an absolute [[contrast medium]] washout of less than 50 percent) | |||
* Hypointensity compared with [[liver]] on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] | |||
* High standardized uptake value (SUV) on [[FDG-PET|FDG]]-[[PET scan|PET-CT]] study | |||
* Evidence of local [[invasion]] or [[Metastasis|metastases]] | |||
| | |||
* [[Androgen|Adrenal androgens]] ([[DHEAS|DHEAS)]] | |||
* [[Androstenedione]] | |||
* Bioavailable [[testosterone]] should be measured in every patient. | |||
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] | |||
* Serum [[estradiol]] in men and postmenopausal women | |||
* [[Cortisol level]] | |||
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Symptoms related to excess [[glucocorticoid]] | |||
* Symptoms related to excess [[mineralocorticoid]] | |||
| | |||
* Round, [[homogeneous]] with sharp margination | |||
* Unilateral with diameter less than 4 cm | |||
* Low unenhanced [[Computed tomography|CT]] attenuation values (<10 HU) | |||
* Rapid [[contrast medium]] washout after administration of contrast | |||
* An absolute [[contrast medium]] washout of more than 50 percent | |||
* [[Chemical shift]]: evidence of [[lipid]] on [[Magnetic resonance imaging|MRI]] | |||
* Isointensity with [[liver]] on both T1 and T2 weighted [[Magnetic resonance imaging|MRI]] sequences | |||
| | |||
* [[Cortisol level]] | |||
* Fasting [[serum]] [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime | |||
* [[Renin]] ([[Plasma renin activity|PRA]]) or plasma renin concentration (PRC): very low in patients with [[primary aldosteronism]], usually less than 1 ng/mL per hour for [[Plasma renin activity|PRA]] and usually undetectable for PRC<ref name="pmid26372319">{{cite journal| author=Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R et al.| title=Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. | journal=J Hypertens | year= 2015 | volume= 33 | issue= 12 | pages= 2500-11 | pmid=26372319 | doi=10.1097/HJH.0000000000000727 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26372319 }}</ref> | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Cushing's syndrome]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]]) | |||
* Proximal [[muscle weakness]] | |||
* A [[round face]] often referred to as a "[[moon face]]" | |||
* Excess [[sweating]] | |||
* [[Headache]] | |||
| | |||
* Imaging may show [[mass]] if presents | |||
| | |||
* 24-hour [[urine]] [[cortisol]] | |||
* Midnight salivary [[cortisol]] | |||
* Low-dose [[dexamethasone]] suppression test; high [[cortisol]] level after the [[dexamethasone]] test is suggestive of [[hypercortisolism]]. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Pheochromocytoma]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* [[Palpitations]] especially in [[Epinephrine|epinephrine-]]<nowiki/>producing [[Tumor|tumors]]. | |||
* [[Anxiety]] often resembling that of a [[panic attack]] | |||
* [[Sweating]] | |||
* [[Headaches]] occur in 90 % of patients. | |||
* Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]]. | |||
* It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients. | |||
| | |||
* Increased [[attenuation]] on non-enhanced [[Computed tomography|CT]] (>20 HU) | |||
* Increased [[mass]] [[vascularity]] | |||
* Delay in [[contrast medium]] washout (10 minutes after administration of [[contrast]], an absolute [[contrast medium]] washout of less than 50 percent) | |||
* High signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] | |||
* [[Cystic]] and [[hemorrhagic]] changes | |||
* Variable size and may be [[bilateral]] | |||
| | |||
* [[Plasma]] fractionated [[Metanephrine|metanephrines]] | |||
* 24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal metastasis]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* [[Symptoms]] and [[signs]] of primary [[malignancy]] especially [[lung cancer]] | |||
* General constitutional symptoms: | |||
**[[Fever]] | |||
**[[Fatigue]] | |||
**[[Weight loss]] | |||
| | |||
* Irregular shape and non-[[homogeneous]] nature | |||
* Tendency to be [[bilateral]] | |||
* High un-enhanced [[Computed tomography|CT]] [[attenuation]] values (>20 HU) and enhancement with [[Contrast medium|intravenous contrast]] on [[Computed tomography|CT]] | |||
* Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent) | |||
* Isointensity or slightly less intense than the [[liver]] on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content) | |||
* Elevated standardized uptake value on [[FDG-PET|FDG]]-[[PET scan]] | |||
| | |||
|} | |||
==References== | ==References== | ||
Line 14: | Line 115: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pathology]] | [[Category:Pathology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] |
Latest revision as of 19:55, 6 March 2019
Adrenal adenoma must be differentiated from other adrenal tumors such as , adrenal metastasis, adrenal medullary tumors, and Cushing's syndrome.
Differential Diagnosis | Clinical picture | Imagings | Laboratory tests |
---|---|---|---|
Adrenocortical carcinoma |
|
|
|
Adrenal adenoma |
|
|
|
Cushing's syndrome |
|
|
|
Pheochromocytoma |
|
|
|
Adrenal metastasis |
|
|
References
- ↑ Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R; et al. (2015). "Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays". J Hypertens. 33 (12): 2500–11. doi:10.1097/HJH.0000000000000727. PMID 26372319.